NanoCell

NanoCell Therapeutics is a biotechnology company pioneering a platform for in vivo cell engineering to treat cancer and autoimmune disorders. The company's core technology, the NanoCell, is a non-viral, synthetic delivery vehicle designed to target and reprogram specific immune cells directly inside the patient's body. This "off-the-shelf" approach aims to eliminate the need for complex and expensive ex vivo manufacturing processes typical of current CAR-T therapies. By facilitating the generation of therapeutic cells in situ, NanoCell seeks to democratize access to advanced cell therapies and expand their application to a wider range of diseases. The platform is designed to be cell-type specific and cargo-agnostic, allowing for the delivery of various genetic payloads to diverse cell populations. Currently in the pre-clinical stage, the company is advancing programs focused on hematological malignancies and immunology.